The 8 analysts offering 12-month price forecasts for Atara Biotherapeutics Inc have a median target of 23.50, with a high estimate of 67.00 and a low estimate of 4.00. The median estimate represents a +350.19% increase from the last price of 5.22.
The current consensus among 9 polled investment analysts is to Buy stock in Atara Biotherapeutics Inc. This rating has held steady since May, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.79
Reporting Date Aug 08
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.